Literature DB >> 33189102

Superior Specimen and Diagnostic Accuracy with Endoscopic Ultrasound-Guided Liver Biopsies Using 19 G versus 22 G Core Needles.

Rucha M Shah1, Jason Schmidt2, Elizabeth John1, Sheila Rastegari3, Priyanka Acharya4, Prashant Kedia1,5.   

Abstract

Background/Aims: Endoscopic ultrasound-guided liver biopsy (EUS-LB) is an effective and safe method of procuring liver tissue. The aims of this study were to assess and compare the outcomes and tissue adequacy of a single-pass, single-actuation, wet suction technique between 19 G and 22 G needles in patients undergoing EUS-LB.
Methods: We performed a prospective case series study of 20 patients undergoing EUS-LB at a single center between September 2017 and April 2020. The primary objective was to evaluate differences in sample adequacy via a single actuation wet suction technique between a 19 G core needle and a 22 G core needle. Adequacy was gauged by cumulative core biopsy length and the number of portal tracts visualized.
Results: The 19 G needle provided a longer core length (2.5 cm vs. 1.2 cm, p<0.0001), more complete portal tracts (5.8 vs. 1.7, p<0.0001), more total tracts (8.8 vs. 3, p<0.0001), and a longer, intact, fragment length (0.75 cm vs. 0.32 cm, p<0.0006). The 19 G needle was superior in providing adequate (60% vs. 5%, p<0.001) and diagnostic pathologic samples (85% vs. 10%, p<0.001). Conclusions: A single-pass, single-actuation, wet suction technique using a 19 G needle is superior to that using a 22 G needle for tissue acquisition and sample adequacy in EUS-LB.

Entities:  

Keywords:  19 G FNB; Endoscopic ultrasound-guided liver biopsy; Liver biopsy

Year:  2020        PMID: 33189102     DOI: 10.5946/ce.2020.212

Source DB:  PubMed          Journal:  Clin Endosc        ISSN: 2234-2400


  1 in total

Review 1.  Update on endoscopic ultrasound-guided liver biopsy.

Authors:  Shiva Rangwani; Devarshi R Ardeshna; Khalid Mumtaz; Sean G Kelly; Samuel Y Han; Somashekar G Krishna
Journal:  World J Gastroenterol       Date:  2022-07-28       Impact factor: 5.374

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.